The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs

Bioorganic & Medicinal Chemistry Letters
2014.0

Abstract

Inhibition of the nonmevalonate pathway (NMP) of isoprene biosynthesis has been examined as a source of new antibiotics with novel mechanisms of action. Dxr is the best studied of the NMP enzymes and several reports have described potent Dxr inhibitors. Many of these compounds are structurally related to natural products fosmidomycin and FR900098, each bearing retrohydroxamate and phosphonate groups. We synthesized a series of compounds with two to five methylene units separating these groups to examine what linker length was optimal and tested for inhibition against Mtb Dxr. We synthesized ethyl and pivaloyl esters of these compounds to increase lipophilicity and improve inhibition of Mtb growth. Our results show that propyl or propenyl linker chains are optimal. Propenyl analog 22 has an IC50 of 1.07 μM against Mtb Dxr. The pivaloyl ester of 22, compound 26, has an MIC of 9.4 μg/mL, representing a significant improvement in antitubercular potency in this class of compounds.

Knowledge Graph

Similar Paper

The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs
Bioorganic & Medicinal Chemistry Letters 2014.0
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs
Bioorganic & Medicinal Chemistry Letters 2011.0
Design of potential bisubstrate inhibitors against Mycobacterium tuberculosis (Mtb) 1-deoxy-d-xylulose 5-phosphate reductoisomerase (Dxr)—evidence of a novel binding mode
MedChemComm 2013.0
Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: An attempt to improve the activity against Mycobacterium tuberculosis
Bioorganic & Medicinal Chemistry Letters 2011.0
Growth inhibition of Mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reducto-isomerase inhibitors, promising anti-mycobacterial agents
European Journal of Medicinal Chemistry 2012.0
Synthesis and evaluation of α,β-unsaturated α-aryl-substituted fosmidomycin analogues as DXR inhibitors
Bioorganic & Medicinal Chemistry Letters 2007.0
Synthesis and Bioactivity of β-Substituted Fosmidomycin Analogues Targeting 1-Deoxy-<scp>d</scp>-xylulose-5-phosphate Reductoisomerase
Journal of Medicinal Chemistry 2015.0
Design, Synthesis, and X-ray Crystallographic Studies of α-Aryl Substituted Fosmidomycin Analogues as Inhibitors of Mycobacterium tuberculosis 1-Deoxy-<scp>d</scp>-xylulose 5-Phosphate Reductoisomerase
Journal of Medicinal Chemistry 2011.0
From Serendipity to Rational Antituberculosis Drug Discovery of Mefloquine-Isoxazole Carboxylic Acid Esters
Journal of Medicinal Chemistry 2009.0
DXR Inhibition by Potent Mono- and Disubstituted Fosmidomycin Analogues
Journal of Medicinal Chemistry 2013.0